SG11202000366WA - Anti-ctla-4 antibodies and uses thereof - Google Patents

Anti-ctla-4 antibodies and uses thereof

Info

Publication number: SG11202000366WA
Authority: SG; Singapore
Prior art keywords: ctla; antibodies
Prior art date: 2017-07-27

Application number

SG11202000366WA

Inventor

Aynur Hermann

Ella Ioffe

Elena Burova

Gavin Thurston

William Olson

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-07-27

Filing date

2018-07-26

Publication date

2020-02-27

2018-07-26 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2020-02-27 Publication of SG11202000366WA publication Critical patent/SG11202000366WA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG11202000366WA 2017-07-27 2018-07-26 Anti-ctla-4 antibodies and uses thereof SG11202000366WA (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201762537753P	2017-07-27	2017-07-27
US201762588853P	2017-11-20	2017-11-20
US201862645284P	2018-03-20	2018-03-20
US201862685599P	2018-06-15	2018-06-15
PCT/US2018/043936 WO2019023482A1 (en)	2017-07-27	2018-07-26	Anti-ctla-4 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
SG11202000366WA true SG11202000366WA (en)	2020-02-27

Family

ID=63165545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202000366WA SG11202000366WA (en)	2017-07-27	2018-07-26	Anti-ctla-4 antibodies and uses thereof

Country Status (18)

Country	Link
US (3)	US10844137B2 (en)
EP (1)	EP3658585A1 (en)
JP (2)	JP7296363B2 (en)
KR (1)	KR102710122B1 (en)
CN (1)	CN111133004B (en)
AU (1)	AU2018307675B2 (en)
BR (1)	BR112020001266A2 (en)
CA (1)	CA3070790A1 (en)
CL (1)	CL2020000216A1 (en)
CO (1)	CO2020000438A2 (en)
IL (1)	IL271882B2 (en)
MA (1)	MA49687A (en)
MY (1)	MY202870A (en)
PH (1)	PH12020500078A1 (en)
SG (1)	SG11202000366WA (en)
TW (1)	TWI799432B (en)
WO (1)	WO2019023482A1 (en)
ZA (1)	ZA202000113B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MD3551660T2 (en)	2016-12-07	2024-03-31	Agenus Inc	Anti-CTLA-4 antibodies and methods of use thereof
TWI799432B (en) *	2017-07-27	2023-04-21	美商再生元醫藥公司	Anti-ctla-4 antibodies and uses thereof
KR20210108978A (en)	2018-12-21	2021-09-03	오제 이뮈노테라프틱스	Bifunctional Anti-PD-1/IL-7 Molecules
IL316757A (en)	2018-12-27	2025-01-01	Gigagen Inc	Anti-ctla-4 binding proteins and methods of use thereof
WO2020165374A1 (en)	2019-02-14	2020-08-20	Ose Immunotherapeutics	Bifunctional molecule comprising il-15ra
SG11202109003QA (en) *	2019-03-06	2021-09-29	Regeneron Pharma	Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
MX2021010997A (en)	2019-03-13	2021-10-01	Merck Sharp & Dohme Llc	COMBINED ANTICANCER THERAPIES INCLUDING CTLA-4 AND PD-1 BLOCKING AGENTS.
BR112022008191A2 (en)	2019-11-08	2022-07-12	Bristol Myers Squibb Co	LAG-3 ANTAGONIST THERAPY FOR MELANOMA
WO2021122866A1 (en)	2019-12-17	2021-06-24	Ose Immunotherapeutics	Bifunctional molecules comprising an il-7 variant
AU2020408678A1 (en) *	2019-12-20	2022-06-23	Merck Sharp & Dohme Llc	Methods for treating cancer using a combination of a PD-1 antagonist, an ILT4 antagonist, and chemotherapeutic agents
CN115997008A (en)	2020-04-22	2023-04-21	艾欧凡斯生物治疗公司	Systems and methods for coordinating the manufacture of cells for patient-specific immunotherapy
AU2021299338A1 (en) *	2020-07-02	2023-02-23	Gigagen, Inc.	Anti-CTLA-4 binding proteins and methods of use thereof
CA3185091A1 (en) *	2020-07-08	2022-01-13	Yuan Cheng	Stabilized formulations containing anti-ctla-4 antibodies
WO2022112198A1 (en)	2020-11-24	2022-06-02	Worldwide Innovative Network	Method to select the optimal immune checkpoint therapies
WO2022127882A1 (en) *	2020-12-17	2022-06-23	南京蓬勃生物科技有限公司	METHOD AND KIT FOR SCREENING CANDIDATE DRUGS TARGETING CD47-SIRPα IMMUNE CHECKPOINT
EP4320156A1 (en)	2021-04-09	2024-02-14	Ose Immunotherapeutics	Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
MX2023011964A (en)	2021-04-09	2024-01-08	Ose Immunotherapeutics	New scaffold for bifunctional molecules with improved properties.
JP2024542536A (en)	2021-11-24	2024-11-15	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Methods for treating cancer using bispecific anti-CD3 x MUC16 and anti-CTLA-4 antibodies - Patents.com
EP4507704A1 (en)	2022-04-15	2025-02-19	Iovance Biotherapeutics, Inc.	Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024003360A1 (en)	2022-07-01	2024-01-04	Institut Curie	Biomarkers and uses thereof for the treatment of neuroblastoma
JP2025525886A (en)	2022-08-02	2025-08-07	オーエスイー・イミュノセラピューティクス	Multifunctional molecules against CD28
CN120584182A (en)	2022-11-21	2025-09-02	艾欧凡斯生物治疗公司	Two-dimensional process of tumor-infiltrating lymphocyte expansion and its therapy
WO2024200823A1 (en)	2023-03-30	2024-10-03	Ose Immunotherapeutics	Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200826A1 (en)	2023-03-30	2024-10-03	Ose Immunotherapeutics	Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
WO2024255467A1 (en) *	2023-06-16	2024-12-19	Genor Biopharma Co., Ltd.	Anti-ccr8 antibody and anti-ccr8/ctla4 bispecific antibody
WO2025140478A1 (en) *	2023-12-29	2025-07-03	百奥泰生物制药股份有限公司	Use of anti-pd-l1/cd47 bispecific antibody in combination therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7109003B2 (en)	1998-12-23	2006-09-19	Abgenix, Inc.	Methods for expressing and recovering human monoclonal antibodies to CTLA-4
HRP20010551B1 (en)	1998-12-23	2013-05-31	Pfizer Inc.	Human monoclonal antibodies to ctla-4
US7087411B2 (en)	1999-06-08	2006-08-08	Regeneron Pharmaceuticals, Inc.	Fusion protein capable of binding VEGF
KR20020047132A (en)	1999-08-24	2002-06-21	메다렉스, 인코포레이티드	Human ctla-4 antibodies and their uses
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US20040101920A1 (en)	2002-11-01	2004-05-27	Czeslaw Radziejewski	Modification assisted profiling (MAP) methodology
JP5848861B2 (en)	2004-04-20	2016-01-27	ジェンマブエー／エスＧｅｎｍａｂＡ／Ｓ	Human monoclonal antibody against CD20
US8257740B1 (en)	2011-08-15	2012-09-04	Gp Medical, Inc.	Pharmaceutical composition of nanoparticles
US8246995B2 (en)	2005-05-10	2012-08-21	The Board Of Trustees Of The Leland Stanford Junior University	Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
AU2007254831B2 (en)	2006-06-02	2012-03-22	Regeneron Pharmaceuticals, Inc.	High affinity antibodies to human IL-6 receptor
WO2009100140A1 (en) *	2008-02-04	2009-08-13	Medarex, Inc.	Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
PL2975051T3 (en)	2009-06-26	2021-09-20	Regeneron Pharmaceuticals, Inc.	Readily isolated bispecific antibodies with native immunoglobulin format
GB201103955D0 (en)	2011-03-09	2011-04-20	Antitope Ltd	Antibodies
TWI682941B (en)	2013-02-01	2020-01-21	美商再生元醫藥公司	Antibodies comprising chimeric constant domains
TWI681969B (en)	2014-01-23	2020-01-11	美商再生元醫藥公司	Human antibodies to pd-1
TWI680138B (en) *	2014-01-23	2019-12-21	美商再生元醫藥公司	Human antibodies to pd-l1
LT3126388T (en) *	2014-03-11	2019-08-26	Regeneron Pharmaceuticals, Inc.	ANTIBODIES AGAINST EGFRVIII AND THEIR USES
TWI754319B (en) *	2014-03-19	2022-02-01	美商再生元醫藥公司	Methods and antibody compositions for tumor treatment
CA2976446A1 (en) *	2015-02-13	2016-08-18	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind ctla4
SG10201913500TA (en) *	2015-05-29	2020-03-30	Agenus Inc	Anti-ctla-4 antibodies and methods of use thereof
US11208483B2 (en) *	2015-11-19	2021-12-28	Shanghai Kanda Biotechnology Co, Ltd.	CTLA-4 antibodies and uses thereof
MX2019006734A (en) *	2016-12-09	2019-10-21	Regeneron Pharma	SYSTEMS AND METHODS FOR SEQUENCING T LYMPHOCYTE RECEPTORS, AND THE USES OF THEM.
TWI799432B (en) *	2017-07-27	2023-04-21	美商再生元醫藥公司	Anti-ctla-4 antibodies and uses thereof

2018
- 2018-07-25 TW TW107125627A patent/TWI799432B/en active
- 2018-07-26 IL IL271882A patent/IL271882B2/en unknown
- 2018-07-26 BR BR112020001266-1A patent/BR112020001266A2/en unknown
- 2018-07-26 AU AU2018307675A patent/AU2018307675B2/en active Active
- 2018-07-26 MA MA049687A patent/MA49687A/en unknown
- 2018-07-26 WO PCT/US2018/043936 patent/WO2019023482A1/en not_active Ceased
- 2018-07-26 CN CN201880051789.XA patent/CN111133004B/en active Active
- 2018-07-26 US US16/046,551 patent/US10844137B2/en active Active
- 2018-07-26 SG SG11202000366WA patent/SG11202000366WA/en unknown
- 2018-07-26 MY MYPI2020000159A patent/MY202870A/en unknown
- 2018-07-26 KR KR1020207005683A patent/KR102710122B1/en active Active
- 2018-07-26 EP EP18752992.0A patent/EP3658585A1/en active Pending
- 2018-07-26 JP JP2020503984A patent/JP7296363B2/en active Active
- 2018-07-26 CA CA3070790A patent/CA3070790A1/en active Pending
2020
- 2020-01-08 ZA ZA2020/00113A patent/ZA202000113B/en unknown
- 2020-01-09 PH PH12020500078A patent/PH12020500078A1/en unknown
- 2020-01-15 CO CONC2020/0000438A patent/CO2020000438A2/en unknown
- 2020-01-24 CL CL2020000216A patent/CL2020000216A1/en unknown
- 2020-10-14 US US17/070,129 patent/US12024570B2/en active Active
2023
- 2023-06-09 JP JP2023095262A patent/JP2023113893A/en active Pending
2024
- 2024-05-20 US US18/669,172 patent/US20250122307A1/en active Pending

Also Published As

Publication number	Publication date
EP3658585A1 (en)	2020-06-03
CN111133004B (en)	2023-12-01
MY202870A (en)	2024-05-27
KR102710122B1 (en)	2024-09-27
US12024570B2 (en)	2024-07-02
US10844137B2 (en)	2020-11-24
JP2023113893A (en)	2023-08-16
CO2020000438A2 (en)	2020-01-31
CA3070790A1 (en)	2019-01-31
TW201920267A (en)	2019-06-01
BR112020001266A2 (en)	2020-07-28
PH12020500078A1 (en)	2020-11-09
CL2020000216A1 (en)	2020-07-10
IL271882B2 (en)	2025-06-01
TWI799432B (en)	2023-04-21
IL271882A (en)	2020-02-27
IL271882B1 (en)	2025-02-01
KR20200032189A (en)	2020-03-25
WO2019023482A1 (en)	2019-01-31
AU2018307675B2 (en)	2024-08-01
CN111133004A (en)	2020-05-08
MA49687A (en)	2020-06-03
JP2020528750A (en)	2020-10-01
ZA202000113B (en)	2021-07-28
US20250122307A1 (en)	2025-04-17
US20210040232A1 (en)	2021-02-11
AU2018307675A1 (en)	2020-02-20
US20190048096A1 (en)	2019-02-14
JP7296363B2 (en)	2023-06-22

Publication	Publication Date	Title
ZA202000113B (en)	2021-07-28	Anti-ctla-4 antibodies and uses thereof
IL290842A (en)	2022-04-01	Anti-cd73 antibodies and uses thereof
ZA202102905B (en)	2023-04-26	Anti-galectin-9 antibodies and uses thereof
ZA202101318B (en)	2023-03-29	Anti-phf-tau antibodies and uses thereof
IL271477A (en)	2020-01-30	Anti-cd166 antibodies and uses thereof
IL273411A (en)	2020-05-31	Anti-pd-l1 antibody and uses thereof
IL268734A (en)	2019-10-31	Anti-lag-3 antibodies and uses thereof
IL265625A (en)	2019-05-30	Activatable anti-ctla-4 antibodies and uses thereof
ZA201902265B (en)	2021-10-27	Anti-pd-1 antibodies and their uses
IL269134A (en)	2019-11-28	Anti-par2 antibodies and uses thereof
SG11201808632YA (en)	2018-10-30	Anti-pacap antibodies and uses thereof
ZA201901935B (en)	2020-11-25	Anti-il-33 antibodies and uses thereof
IL273157A (en)	2020-04-30	Axl-specific antibodies and uses thereof
IL272476A (en)	2020-03-31	Anti-apelin antibodies and uses thereof
IL274502A (en)	2020-06-30	Anti-ox40 antibodies and uses thereof
IL266082A (en)	2019-06-30	Anti-chikv antibodies and uses thereof
IL266049A (en)	2019-06-30	Anti-o1 antibodies and uses thereof
IL264417A (en)	2019-02-28	Anti-o2 antibodies and uses thereof
IL274202A (en)	2020-06-30	Anti-glyco-muc1 antibodies and their uses
GB201712032D0 (en)	2017-09-06	Antibodies and uses thereof
IL266059A (en)	2019-06-30	Anti-rankl antibodies and uses thereof
HK40030249A (en)	2021-02-26	Anti-ctla-4 antibodies and uses thereof